Med-Metrix Acquires Vitalware from Health Catalyst — What It Means for Mid-Revenue Cycle

Health Catalyst is selling Vitalware — the 5x Best in KLAS chargemaster platform it bought for $70M in 2020 — to PE-backed services operator Med-Metrix for $147 million in cash. The proceeds go straight to retiring Health Catalyst's $160M term loan. This isn't just a vendor shuffle. It's a debt-driven exit that hands a profitable mid-revenue cycle software business to an operator built to run it.

The Deal

Med-Metrix, LLC — backed by Harvest Partners and A&M Capital Partners — announced June 4, 2026 it has entered into a definitive agreement to acquire Vitalware from Health Catalyst (NASDAQ: HCAT) for $147 million in cash. Health Catalyst has filed an 8-K with the SEC. Raymond James acted as exclusive financial advisor to Health Catalyst; Latham & Watkins LLP provided legal counsel. The transaction is expected to close in 2026, subject to customary closing conditions. Vitalware's leadership team and employees are expected to be integrated into Med-Metrix post-close.

Why Health Catalyst Is Letting It Go

Health Catalyst paid roughly $70 million for Vitalware in 2020 with a thesis that combining a data analytics platform with mid-revenue cycle workflow software would create an integrated offering hospitals couldn't get elsewhere. Six years later, they're selling it for $147M — roughly doubling their money on paper — but the real story is what they're doing with the proceeds.

The entire $147M, combined with existing cash, goes directly toward repaying and terminating Health Catalyst's $160 million senior secured term loan (outstanding principal as of March 31, 2026). This isn't a strategic pivot dressed up as focus — it's a deleveraging transaction. Health Catalyst exits with a clean balance sheet and can finally fund its clinical AI roadmap without a nine-figure debt load hanging over it.

The business case is straightforward: Vitalware generated ~$37M in revenue in FY2025. At a $147M exit, that's roughly a 4x revenue multiple — solid for a software business in this environment. Health Catalyst takes the gain, kills the debt, and refocuses on what it was actually built to do: 18 years of healthcare data infrastructure, $2.8 billion in documented outcomes, and a clinical AI platform it couldn't fully invest in while carrying that loan.

CEO Ben Albert framed it diplomatically: "This strategic move opens our next phase, and we have found a tremendous partner in Med-Metrix to take Vitalware forward." The subtext: Vitalware needed an operator who would invest in it as a core product, not carry it as a non-core asset.

What Med-Metrix Gets

Med-Metrix already operates as an end-to-end RCM and business intelligence services platform for health systems and physician groups. What they've been missing is proprietary mid-revenue cycle software — the kind that sits in the workflow daily, owns the chargemaster, and drives coding accuracy before the claim ever drops.

Vitalware fills that gap directly:

• Chargemaster management: 5x Best in KLAS. Widely adopted across hospitals and health systems for CDM governance, charge capture accuracy, and regulatory compliance.
• Coding workflow tools: Bridges clinical documentation and the claim — the exact point where revenue leakage typically starts.
• Price transparency: A compliance requirement that most health systems are still struggling to operationalize cleanly. Vitalware has tooling here.
• Revenue integrity analytics: Flags where charge capture is breaking down before it hits accounts receivable.

Med-Metrix Co-President Rob Wright put it plainly: "By integrating their impressive software capabilities, we are better positioned to help providers improve reimbursement accuracy, manage compliance risk, and capture the full value of care delivered."

What This Means If You're a Vitalware Client

If Vitalware's chargemaster or revenue integrity tools are in your stack, here's what to watch:

• Short term, nothing changes operationally. The deal is still pending close and the Vitalware team is expected to integrate — not be restructured out. Your account reps and support contacts should remain intact initially.
• Med-Metrix is an operator, not a software company. Expect them to push tighter integration between the software and services offerings. If you're currently a pure software client with no Med-Metrix services relationship, expect a commercial conversation about the broader platform.
• Product investment direction may shift. Health Catalyst was a public data company. Med-Metrix is a PE-backed services operator. Investment priorities may tilt toward features that support services delivery rather than standalone analytics depth. Worth watching over 12–18 months.
• Pricing structure is an open question. Post-close integration often brings pricing model reviews, particularly when the acquirer is building toward a bundled services + software offer.

The Bigger Picture: Mid-Revenue Cycle Is the Next Battleground

This deal is the latest in a string of moves signaling that the mid-revenue cycle — charge capture, CDM, coding accuracy, revenue integrity — is where PE and strategic capital is concentrating right now.

The back end of revenue cycle (AR follow-up, denial management, collections) has been outsourced for decades. The front end (prior auth, eligibility) is being disrupted by AI. That leaves the middle — the charge-to-claim workflow — as the highest-value, least-automated layer in the stack. Whoever owns that workflow with software, not just services, has leverage.

Med-Metrix just bought that leverage.

For health system RCM leaders: know who owns your CDM platform and what their roadmap looks like. Ownership changes have a way of accelerating or derailing product timelines in ways that directly affect your net revenue yield.

Published by RevCycleAI Research · June 5, 2026 · Source: Med-Metrix Press Release